Calcium Channel Agonist

Calcium Channel Agonists (23):

Cat. No.	Product Name	Effect	Purity

HY-10588

Bay K 8644	Agonist	99.96%
Bay K 8644 ((±)-Bay K 8644) is a racemate consisting of two isomers (R)-(+)-Bay-K-8644 and (S)-(-)-Bay-K-8644. Bay K 8644 is a L-type Ca²⁺ channel agonist with an EC₅₀ of 17.3 nM. Bay K 8644 increases Ca²⁺ influx through sarcolemmal Ca²⁺ channels by increasing the open time of the channel. Bay K 8644 has vasoconstrictive effects.

HY-113308A

Taurolithocholic acid sodium salt	Agonist	99.81%
Taurolithocholic acid sodium salt, a potent cholestatic agent, is a potent Ca²⁺ agonist.

HY-15124

(S)-(-)-Bay-K-8644	Agonist	98.81%
(S)-(-)-Bay-K-8644 is an agonist of L-type Ca²⁺ channel. (S)-(-)-Bay-K-8644 activates Ba²⁺ currents (I_Ba) (EC₅₀=32 nM).

HY-103307

FPL64176	Agonist	99.86%
FPL64176, a nondihydropyridine compound, is a potent agonist of L-type Ca²⁺ channels with an EC₅₀ value of 16 nM.

HY-12498

GV-58	Agonist	99.22%
GV-58 is a novel N- and P/Q-type calcium (Ca²⁺) channel agonist with EC₅₀s of 7.21 and 8.81 μM, respectively. GV-58 slows the deactivation of channels, resulting in a large increase in presynaptic Ca²⁺ entry during activity. GV-58 can be used in lambert-eaton myasthenic syndrome (LEMS) research.

HY-41076

Ca2+ channel agonist 1	Agonist	99.71%
Ca²⁺ channel agonist 1 is an agonist of N-type Ca²⁺ channel and an inhibitor of Cdk2, with EC₅₀s of 14.23 μM and 3.34 μM, respectively, and is used as a potential treatment for motor nerve terminal dysfunction.

HY-138119

γ-Glutamylserine	Agonist	98.35%
γ-Glutamylserine (γ-Glu-Ser) is a calcium receptor activator. γ-Glutamylserine can be used for Parkinson's disease research, as well as diabetes or obesity study.

HY-B0106A

Etiracetam	Agonist	99.91%
Etiracetam (UCB 6474) is an acetylcholine agonist and a nootropic drug of the racetam family. Less active than its S-enantiomer Levetiracetam (UCB L059).

HY-113308

Taurolithocholic acid	Agonist	99.7%
Taurolithocholic acid is a bile acid that has the activity of increasing cell viability, inducing the S phase of the cell cycle, and promoting DNA synthesis in a concentration-dependent manner in the intrahepatic cholangiocarcinoma cell line RMCCA-1. It can also increase the phosphorylation of EGFR and ERK 1/2 and the expression of cyclin D1 in RMCCA-1 cells, and its induced RMCCA-1 cell growth can be inhibited by specific antagonists and inhibitors.

HY-P5114

Maurocalcine	Agonist
Maurocalcine is an agonist of ryanodine receptor (RyR) channel types 1, 2 and 3 with cellular permeability. Maurocalcine induces [³H]ryanodine binding on RyR1 with an EC₅₀ value of 2558 nM. Maurocalcine exhibits a apparent affinity of 14 nM for RyR2. Maurocalcine can be applied to in vivo cell tracking or other cell imaging techniques.

HY-P5114A

Maurocalcine TFA	Agonist
Maurocalcine TFA is an agonist of ryanodine receptor (RyR) channel types 1, 2 and 3 with cellular permeability. Maurocalcine TFA induces [³H]ryanodine binding on RyR1 with an EC₅₀ value of 2558 nM. Maurocalcine TFA exhibits a apparent affinity of 14 nM for RyR2. Maurocalcine TFA can be applied to in vivo cell tracking or other cell imaging techniques.

HY-113308AS

Taurolithocholic acid-d₄ sodium	Agonist
Taurolithocholic acid-d₄ (sodium) is the deuterium labeled Taurolithocholic acid (sodium salt). Taurolithocholic acid sodium salt, a potent cholestatic agent, is a potent Ca2+ agonist[1].

HY-167925

Rec 15/2615	Agonist
Rec 15/2615 is a potent α(1)-adrenergic agonist that stimulates small cholangiocyte proliferation through the activation of calcium-dependent signaling pathways.

HY-113308AS2

Taurolithocholic acid-d₄-1 sodium	Agonist
Taurolithocholic acid-d₄-1 (sodium) is the deuterium labeled Taurolithocholic acid. Taurolithocholic acid sodium salt, a potent cholestatic agent, is a potent Ca2+ agonist[1].

HY-113308S

Taurolithocholic acid-d₅	Agonist
Taurolithocholic acid-d₅ is deuterium labeled Taurolithocholic acid.

HY-113308S1

Taurolithocholic acid-d₄	Agonist
Taurolithocholic acid-d₄ is deuterium labeled Taurolithocholic acid.

HY-B0106AR

Etiracetam (Standard)	Agonist
Etiracetam (Standard) is the analytical standard of Etiracetam. This product is intended for research and analytical applications. Etiracetam (UCB 6474) is an acetylcholine agonist and a nootropic drug of the racetam family. Less active than its S-enantiomer Levetiracetam (UCB L059).

HY-B0106AS

Etiracetam-d₃	Agonist
Etiracetam-d₃ is the deuterium labeled Etiracetam. Etiracetam (UCB 6474) is an acetylcholine agonist and a nootropic drug of the racetam family. Less active than its S-enantiomer Levetiracetam (UCB L059)[1].

HY-136677

Lnd 796	Agonist
LND 796 is an aminosteroidal derivative with positive inotropic effects similar to those of digitalis. It exhibits electrophysiological, toxic, and inotropic effects in normal and partially potassium-depolarized ventricular muscles. LND 796 requires higher concentrations than digoxin to induce the same toxic symptoms. It exhibits a concentration-dependent positive inotropic effect on guinea pig papillary muscles in normal potassium solution. In partially potassium-depolarized papillary muscles, LND 796 enhances both components of contraction and increases the amplitude of slow action potentials. The mechanism of positive inotropic action of LND 796 involves enhanced calcium entry in calcium channels and inhibition of sodium-potassium ATPase. Due to its expanded positive inotropic range, LND 796 may have potential application in the treatment of congestive heart failure.

HY-126551

Butenoyl-PAF	Agonist
Butenoyl-PAF is a phospholipid analog of platelet activating factor (PAF-like) that is generated in oxidized low-density lipoprotein (DLDR). Butenoyl-PAF can activate cells that express human PAF receptors, such as neutrophils, monocytes, and platelets, and it stimulates an increase in intracellular calcium ion concentration.

Name
Email *

	Sorry, but the email address you supplied was invalid.